|1.||Berry, Robert E: 1 article (07/2011)|
|2.||Brailey, Jacqueline L: 1 article (07/2011)|
|3.||Fritz, Bradley G: 1 article (07/2011)|
|4.||Montfort, William R: 1 article (07/2011)|
|5.||Hu, Xiaohui: 1 article (07/2011)|
|6.||Walker, F Ann: 1 article (07/2011)|
|7.||Hellstrom, Wayne J G: 1 article (05/2010)|
|8.||Kadowitz, Philip J: 1 article (05/2010)|
|9.||Gur, Serap: 1 article (05/2010)|
|10.||Dumitrascu, Rio: 1 article (10/2009)|
|1.||Cardiovascular Diseases (Cardiovascular Disease)
05/01/2010 - "BAY 58-2667, HMR-1766, S-3448, A-778935) in the treatment of cardiovascular diseases. "
01/01/2007 - "HMR1766 is a new nitric oxide (NO)-independent activator of soluble guanylyl cyclase (sGC) in development for the treatment of cardiovascular diseases and chronic heart failure. "
07/05/2011 - "Oxidation and loss of heme in soluble guanylyl/guanylate cyclase (sGC), the nitric oxide receptor, is thought to be a major contributor to cardiovascular disease and is the target of compounds BAY 58-2667 and HMR1766. "
|2.||Renal Insufficiency (Renal Failure)
|3.||Pulmonary Hypertension (Ayerza Syndrome)
10/01/2009 - "In isolated perfused mouse lungs from control animals, HMR1766 dose-dependently inhibited the pressor response of acute hypoxia. "
10/01/2009 - "In mice with PH induced by chronic hypoxia, we examined the acute and chronic effects of the soluble guanylate cyclase (sGC) activator HMR1766 on hemodynamics and pulmonary vascular remodeling. "
10/01/2009 - "The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice."
|1.||Guanylate Cyclase (Guanylyl Cyclase)
|3.||soluble guanylyl cyclase
|4.||Nitric Oxide (Nitrogen Monoxide)
|6.||3- (2- (2,2- dimethylpropylsulfanyl)pyridin- 3- yl)- N- (3- hydroxycyclohexyl)acrylamide